Real-life outcomes of maraviroc-based regimens in HIV-1-infected individuals.
OBJECTIVE
The use of maraviroc in our unit was reviewed with regard to efficacy and safety and also reviewed with regard to how our experience reflects the data presented in clinical trials.


METHODS
We utilized the pharmacy dispensary system to identify any patient dispensed maraviroc and conducted a case note review.


RESULTS
We identified 27 patients who have been prescribed maraviroc as part of their antiretroviral treatment. In all, 81% were men and 81% were white British. There were 26 treatment-experienced patients and 1 treatment-naive patient. At the time of switching to maraviroc, 17 patients had detectable HIV viral loads and 10 had HIV RNA levels <40 copies/mL. At completion, 6 undetectable patients maintained undetectability and 10 viremically detectable patients achieved viral suppression. Maraviroc was discontinued in 18.5% of patients and the only adverse drug reaction reported was a rash.


CONCLUSIONS
The experience of using maraviroc by our study participants shows similarity in terms of efficacy and safety to the MERIT and MOTIVATE clinical trials.
Monsall Unit, North Manchester General Hospital, Manchester, UK.
Zahir Osman Eltahir
ZO
Babiker
Sam Thomas
ST
Douthwaite
Lucy Elizabeth
LE
Collier
Ashley
A
Pennell
Alison J
AJ
Uriel
Edmund
E
Wilkins
D000328:Adult; D018791:CD4 Lymphocyte Count; D003510:Cyclohexanes / Q000627:therapeutic use*; D004342:Drug Hypersensitivity; D004359:Drug Therapy, Combination; D005076:Exanthema / Q000139:chemically induced; D005260:Female; D023581:HIV Fusion Inhibitors / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1 / Q000235:genetics; D006801:Humans; D008297:Male; D000077592:Maraviroc; D008875:Middle Aged; D012367:RNA, Viral / Q000097:blood; D012189:Retrospective Studies; D014230:Triazoles / Q000627:therapeutic use*; D019562:Viral Load; D055815:Young Adult
D003510:Cyclohexanes; D023581:HIV Fusion Inhibitors; D012367:RNA, Viral; D014230:Triazoles; D000077592:Maraviroc